腺病毒介导的激活大鼠阴茎海绵体平滑肌细胞中NO/cGMP通路的实验研究

袁慧星; 王涛; 詹鹰; 王少刚; 刘继红; 叶章群

腺病毒介导的激活大鼠阴茎海绵体平滑肌细胞中NO/cGMP通路的实验研究

- 华中科技大学同济医学院附属同济医院泌尿外科(武汉, 430030)
基金项目:
国家自然科学基金（编号30872574）

详细信息

通讯作者: 刘继红,E-mail:jhliu@tjh.tjmu.edu.cn

中图分类号: R697

收稿日期: 2012-09-24

Study of adenovirus-mediated saRNA activating NO/cGMP pathway in rat corpus cavernosum smooth muscle cells

- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

More Information

Corresponding author: LIU Jihong, E-mail: jhliu@tjh.tjmu.edu.cn

Received Date: 24 September 2012

摘要

摘要: 目的：探讨靶向大鼠iNOS基因的shRNA重组腺病毒载体对大鼠阴茎海绵体平滑肌细胞iNOS基因的激活作用，为阴茎勃起功能障碍（ED）的基因治疗提供实验依据。方法：将前期构建的重组腺病毒Ad5-iNOSrshRNA-EGFP（AdU6/shiNOS）和对照病毒AdU6/shControl，分别转染大鼠阴茎海绵体平滑肌细胞，分别在不同病毒MOI（25，50，75）值下72小时后采样检测。采用realtime RT-PCR半定量检测AdU6/shiNOS对细胞iNOS基因mRNA表达影响；Western-blot法检测海绵体平滑肌细胞iNOS蛋白表达变化。然后培养基中加L-Arg（10 mmol/L），用酶联免疫法检测病毒转染72小时后海绵体平滑肌细胞内cGMP的浓度变化，记录AdU6/shiNOS对平滑肌细胞内 cGMP的影响。结果：AdU6/shiNOS转染大鼠阴茎海绵体平滑肌细胞72小时后，和空白对照组、阴性对照组相比iNOS 基因在mRNA和蛋白表达水平均显著上调（P<0.05），呈剂量依赖性，MOI=75时RNAa效果最好。而且转染72小时后，实验组原代平滑肌细胞内cGMP水平显著高于对照组及空白组（P<0.05）。结论：利用腺病毒介导的RNAa技术，提高海绵体平滑肌细胞iNOS基因表达获得成功，可以增加阴茎海绵体平滑肌细胞cGMP水平，激活了NO/cGMP通路，这为勃起功能障碍的基因治疗研究开辟了新的方向。
- 勃起功能障碍 /
- 基因治疗 /
- RNA激活 /
- iNOS基因 /
- 大鼠
Abstract: Objective: To explore the activation of recombinant adenovirus expressing short hairpin RNA of rat inducible nitric oxide synthase to iNOS gene in rat corpus cavernosum smooth muscle cells in order to provide experimental evidence for erectile dysfunction gene therapy. Methods: The pre-constructed adenovirus Ad5-iNOS-shRNA-EGFP(AdU6/shiNOS) and the control virus AdU6/shControl transfected into rat cavernous smooth muscle cells.Cells were examined for iNOS expression by Real-time quantitative PCR and western blotting and different MOI(25, 50, 75) after 72 hours.Cells were then treated with 10 mmol/L L-arginine. Cyclic guanosine monophosphate(cGMP) with enzyme immunoassay (EIA) system at 72 hours after transfecting was analyzed and the effect of AdU6/shiNOS on the cGMP of smooth muscle cell was recorded. Results: Compared with mock group and control group, AdU6/shiNOS transfected rat corpus cavernosum smooth muscle cells after 72 hours, iNOS gene expression at the mRNA and protein were significantly increased in a dose-dependent(P<0.05), MOI=75 works best for RNAa. Corpus cavernosum smooth muscle cells transfected with AdU6/shiNOS showed an increase of cGMP level compared with corpus cavernosum smooth muscle cells transfected with control vector and the mock group(P<0.05). Conclusion: Success using of adenovirus-mediated RNAa technology to improve the iNOS gene expression in corpus cavernosum smooth muscle cells can increase the cGMP level in corpus cavernosum smooth muscle cell, and activative the NO/cGMP pathway, which opened a new research direction for the gene treatment of erectile dysfunction.
- erectile dysfunction /
- gene therapy /
- RNA activating /
- inducible nitric oxide synthase /
- rat

HTML全文

参考文献(15)

[1]	Moreland R B. Pathophysiology of erectile dysfunction:the contributions of trabecular structure to function and the role of functional antagonism[J]. Int J Impot Res, 2000,12:39-46.
[2]	Gonzalez-Cadavid N F, Rajfer J. Molecular pathophysiology and gene therapy of aging-related erectile dysfunction[J]. Exp Gerontol, 2004, 39:1705-1712.
[3]	Li L C, Okino S T, Zhao H, et al. Small dsRNAs induce transcriptional activation in human cells[J]. Proc Natl Acad Sci U S A, 2006, 103:17337-17342.
[4]	Janowski B A, Younger S T, Hardy D B, et al. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs[J]. Nat Chem Biol, 2007, 3:166-173.
[5]	袁慧星, 王涛, 刘继红, 等. 大鼠诱导型一氧化氮合酶短发夹环RNA质粒的构建及鉴定[J]. 临床泌尿外科杂志, 2010,12(25):942-944.
[6]	袁慧星, 王涛, 刘继红, 等. 靶向大鼠诱导型一氧化氮合酶基因的shRNA重组腺病毒载体的构建及鉴定[J]. 中华实验外科杂志, 2011, 1(28):133-135.
[7]	宋鲁杰, 徐月敏, 傅强. 体外分离培养兔阴茎海绵体平滑肌细胞的纯度分析[J]. 中国男科学杂志, 2007, 21(11):1-5.
[8]	Bumcrot D, Manoharan M, Koteliansky V, et al. RNAi therapeutics:a potential new class of pharmaceutical drugs[J]. Nat Chem Biol, 2006, 2:711-719.
[9]	Dykxhoorn D M, Lieberman J.Running interference:prospects and obstacles to using small interfering RNAs as small molecule drugs[J]. Annu Rev Biomed Eng, 2006, 8:377-402.
[10]	Li L C. The multifaceted small RNAs[J]. RNA Biol, 2008, 5:61-64.
[11]	Turunen M P, Lehtola T, Heinonen S E, et al. Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism:a novel example of epigenetherapy[J]. Circ Res, 2009, 105:604-609.
[12]	Davila H H, Magee T R, Vernet D, et al. Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease[J]. Biol Reprod, 2004, 71:1568-1577.
[13]	Garbán H, Marquez D, Magee T, et al. Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy of erectile dysfunction[J]. Biol Reprod, 1997, 56:954-963.
[14]	Chancellor M B, Tirney S, Mattes C E, et al. Nitric oxide synthase gene transfer for erectile dysfunction in a rat model[J]. BJU Int, 2003, 91:691-696.
[15]	Tirney S, Mattes C E, Yoshimura N, et al. Nitric oxide synthase gene therapy for erectile dysfunction:comparison of plasmid,adenovirus,and adenovirus-transduced myoblast vectors[J]. Mol Urol, 2001, 5:37-43.